Lifeboat Foundation

The early-stage development of many age-targeting compounds often involves studies of their effects on the lifespan of the transparent nematode (worm) model Caenorhabditis elegans. A highly manual process, this exercise is time-consuming and only produces data on one endpoint – lifespan.

Durham University associate professors David Weinkove and Chris Saunter invented a technology that automates measurements of movement in many large populations of worms simultaneously. Crucially, this technology goes beyond measuring lifespan, also capturing information about how worms’ health declines as they age – their healthspan.

Longevity. Technology: Together, Weinkove and Saunter have co-founded a spinout company called Magnitude Biosciences, leveraging their innovative platform to test drugs and other interventions for their capacity to prolong healthspan. We caught up with Weinkove to learn more about the background to the company and where it goes from here.

Remedium Bio has announced that it has closed more than $2.3m in its expanded seed round financing. Funding from the raise is being used to study Remedium’s lead product, a single-injection gene therapy potentially capable of reversing cartilage loss; this research is being conducted in collaboration with scientists from Tufts University School of Medicine who are engaged in researching rheumatic disorders.

The financing was led by Sherwood Ventures and included participation from, LongevityTech. Fund, Primo Medical Group, Angel Star Ventures, Apis Health Angels, MicroVentures, and Guindy Alumni Angels.

Longevity. Technology: Remedium’s pipeline includes therapeutic indications in osteoarthritis, diabetes, stroke and other large unmet clinical needs.

A biotech firm wants to create “synthetic” human embryos that would be used to harvest organs in order to facilitate transplants and treat conditions such as infertility, genetic disease, and aging, according to researchers.

The Israel-based company, Renewal Bio, claimed that it successfully used advanced stem cell technology and artificial wombs in order to grow mouse embryos which continued to develop for several days.

We all age. But the process of aging may be different in the year 2050 thanks to advances in medical tech.

Star Scientific invents a catalyst that in the presence of hydrogen and oxygen heats to 700 Celsius. That’s enough heat to drive a steam turbine for power generation.

Star Scientific is a 25-year-old research laboratory north of Sydney, Australia. The company is one of many trying to make existing power plants carbon-free. This includes old coal-fired thermal power stations which remain among the biggest contributors to greenhouse gas emissions on the planet. Star has invented a patented non-polluting catalyst which it calls HERO® which is an acronym for Hydrogen Energy Release Optimizer. It uses hydrogen without producing combustion.

Mars Food Australia, the subsidiary of the global food giant, is using HERO® to help decarbonize its processes. The 18-month pilot project is the first step in developing alternative heat sources for the food industry. Bill Heague who is General Manager of Mars in Australia states, “Thermal energy is crucial to the business of cooking food and this technology has the capability to create limitless heat without any combustion and zero emissions.”

Continue reading “Can We Adapt Old Power Plants to Run on Green Hydrogen?” »

“We took skin biopsies from patients living with Huntington’s disease and reprogrammed the skin biopsies into neurons. We then compared these neurons with reprogrammed neurons from healthy people. The results are very interesting. We have found several defects that explain some of the disease mechanisms in neurons from patients with Huntington’s disease. Among other things, we observed that neurons from patients with Huntington’s disease show problems in breaking down and recycling a particular kind of protein – which can lead to a lack of energy in these cells”, says Johan Jakobsson, professor of neuroscience at Lund University.

The researchers have also measured the biological age of the cells and observed that the reprogrammed neurons retain their biological age, which is significant if they are to be used for research in the new model system.

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

Bristle Discount Link (Oral microbiome quantification):
ConquerAging15
https://www.bmq30trk.com/4FL3LK/GTSC3/

Continue reading “Glycine + N-Acetyl Cysteine Supplementation Increases Lifespan” »

Reaching the golden years doesn’t always feel so golden. Growing older introduces a range of health challenges, including being at increased risk for developing chronic diseases and having reduced immunity to infection. But while scientists have traditionally viewed the unpleasant aspects of aging as inevitable, new research could reveal how to substantially delay aging and improve the health of older individuals.

Chronic inflammation, one of the major hallmarks of aging, is thought to be partly caused by senescent cells that may accumulate in older individuals. Now, Yale researchers have received a grant [U54-AG079759] from the National Institutes of Health (NIH) Common Fund’s Cellular Senescence Network Program (SenNet) to study these specialized cells. The grant will further scientists’ knowledge of the mechanisms behind aging and potential therapies for dampening inflammation associated with old age. The SenNet is based on ‘Geroscience,’ an approach that intersects basic aging biology, chronic disease, and health to understand the cellular mechanisms that make aging a major risk factor for common chronic conditions of older people. Support by the NIH Common Fund shows the NIH’s commitment to Geroscience as a complex, high priority topic in biomedical research.

“A number of diseases that increase in older people may have a unifying underlying mechanism having to do with senescence,” says Ruth Montgomery, PhD, professor of medicine and of epidemiology (microbial diseases), and co-PI of the project. “If we are able to understand and address this, we may be able to reduce the incidence of a number of diseases, including cancers and heart diseases.”

Christian Angermayer, founder of talks longevity investment, optimism on SPAC deal and light at the end of the tunnel for the biotech market.
One of the speakers at October’s Rejuvenation Startup Summit in Berlin is the entrepreneur and investor, Christian Angermayer.

With more than $3 billion under management through his Apeiron Investment Group, Angermayer is a major figure in the longevity sector through his platform biotech companies Cambrian and Rejuveron – building on his belief that everyone wants to live healthier, happier and longer lives.

Continue reading “Christian Angermayer on longevity and biotech investment” »